COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Effects of Atorvastatin Versus Probucol on Small Dense LDL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00276133
Recruitment Status : Completed
First Posted : January 12, 2006
Last Update Posted : May 9, 2007
Information provided by:
Yokohama City University Medical Center

Brief Summary:
Small dense low-density lipoprotein (LDL) plays an important role in causing glomerular injury through conversion to an oxidatively modified form of LDL. However, few studies evaluated the effects of antilipidemic agents on the LDL particle size and renoprotective actions in hyperlipidemic patients with non-diabetic nephropathy.

Condition or disease Intervention/treatment Phase
Chronic Nephropathy Drug: Effects of atorvastatin versus probucol on small dense LDL Phase 4

Detailed Description:
The study is a randomized crossover trial comparing the effect of atorvastatin (10 mg/day) and probucol (500 mg/day) for 24 weeks in 30 patients (urinary albumin excretion 0.3-2.0 g/day, and creatinine clearance > 30 ml/min/1.73 m2 or serum creatinine concentration < 2 mg/L). Lipid parameters, mean LDL particle diameter, creatinine clearance, and urinary albumin to creatinine excretion ratio are measured before and during treatment periods. It will be evaluated that, first, whether atorvastatin and probucol significantly reduce serum total cholesterol and LDL cholesterol concentrations, second, whether atorvastatin and probucol significantly increase the LDL particle size, third, whether significant differences in urinary albumin/creatinine excretion ratio and creatinine clearance are observed in both groups during treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effects of Atorvastatin Versus Probucol on Low-Density Lipoprotein Subtype Distribution and Renal Function in Hyperlipidemic Patients With Non-Diabetic Nephropathy
Study Start Date : January 2004
Actual Study Completion Date : May 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Diseases

Primary Outcome Measures :
  1. Normalization of serum cholesterol concentrations [ Time Frame: One year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Hyperlipidemic patients with non-diabetic nephropathy

Exclusion Criteria:

  • Endocrinological, hematological or hepatic disease
  • Cerebral infarction or hemorrhage
  • Homozygous familial hypercholesterolemia
  • Uncontrolled hypertension
  • Myocardial infarction occurring within the previous 6 months
  • Unstable angina
  • Diabetic nephropathy
  • Abnormal thyroid function
  • Receiving steroids or immunosuppressive agents

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00276133

Layout table for location information
Yokohama City University Center Hospital
Yokohama, Kanagawa, Japan, 232-0024
Sponsors and Collaborators
Yokohama City University Medical Center
Layout table for investigator information
Principal Investigator: Gen Yasuda, MD Yokohama City University Center Hospital
Layout table for additonal information Identifier: NCT00276133    
Other Study ID Numbers: 7332-1
First Posted: January 12, 2006    Key Record Dates
Last Update Posted: May 9, 2007
Last Verified: May 2007
Keywords provided by Yokohama City University Medical Center:
small dense LDL
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Urologic Diseases
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors
Protective Agents
Physiological Effects of Drugs